Suppr超能文献

吸入颗粒所遇到的障碍。

Barriers that Inhaled Particles Encounter.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, Texas, USA.

出版信息

J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):299-306. doi: 10.1089/jamp.2024.27498.bp.

Abstract

Inhalable particulate drug carriers-nano- and micro-particles, liposomes, and micelles-should be designed to promote drug deposition in the lung and engineered to exhibit the desired drug release property. To deposit at the desired site of action, inhaled particles must evade various lines of lung defense, including mucociliary clearance, entrapment by mucus layer, and phagocytosis by alveolar macrophages. Various physiological, mechanical, and chemical barriers of the respiratory system reduce particle residence time in the lungs, prevent particle deposition in the deep lung, remove drug-filled particles from the lung, and thus diminish the therapeutic efficacy of inhaled drugs. To develop inhalable drug carriers with efficient deposition properties and optimal retention in the lungs, particle engineers should have a thorough understanding of the barriers that particles confront and appreciate the lung defenses that remove the particles from the respiratory system. Thus, this section summarizes the mechanical, chemical, and immunological barriers of the lungs that inhaled particles must overcome and discusses the influence of these barriers on the fate of inhaled particles.

摘要

可吸入颗粒药物载体 - 纳米和微颗粒、脂质体和胶束 - 应设计为促进药物在肺部的沉积,并设计为表现出所需的药物释放特性。为了在预期的作用部位沉积,吸入的颗粒必须逃避各种肺部防御机制,包括黏液纤毛清除、被黏液层捕获和肺泡巨噬细胞吞噬。呼吸系统的各种生理、机械和化学屏障会减少颗粒在肺部的停留时间,防止颗粒在肺部深部沉积,将充满药物的颗粒从肺部清除,从而降低吸入药物的治疗效果。为了开发具有高效沉积性能和在肺部最佳保留的可吸入药物载体,颗粒工程师应该充分了解颗粒所面临的障碍,并了解从呼吸系统中清除颗粒的肺部防御机制。因此,本节总结了吸入颗粒必须克服的肺部机械、化学和免疫学屏障,并讨论了这些屏障对吸入颗粒命运的影响。

相似文献

1
Barriers that Inhaled Particles Encounter.吸入颗粒所遇到的障碍。
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):299-306. doi: 10.1089/jamp.2024.27498.bp.
4
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
6
Targeting Immune Cells.靶向免疫细胞。
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):328-337. doi: 10.1089/jamp.2024.63954.es.
7
Nebuliser systems for drug delivery in cystic fibrosis.雾化器系统在囊性纤维化中的药物输送。
Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3.
8
Inhaled hyperosmolar agents for bronchiectasis.用于支气管扩张症的吸入性高渗剂
Cochrane Database Syst Rev. 2006 Apr 19(2):CD002996. doi: 10.1002/14651858.CD002996.pub2.
9
Nebulised hypertonic saline for cystic fibrosis.雾化高渗盐水用于囊性纤维化
Cochrane Database Syst Rev. 2018 Sep 27;9(9):CD001506. doi: 10.1002/14651858.CD001506.pub4.
10
Short-acting inhaled bronchodilators for cystic fibrosis.短效吸入性支气管扩张剂在囊性纤维化中的应用。
Cochrane Database Syst Rev. 2022 Jun 24;6(6):CD013666. doi: 10.1002/14651858.CD013666.pub2.

本文引用的文献

1
Barrier function of airway tract epithelium.气道上皮的屏障功能。
Tissue Barriers. 2013 Oct 1;1(4):e24997. doi: 10.4161/tisb.24997. Epub 2013 May 30.
3
Trachea: anatomy and physiology.气管:解剖与生理。
Thorac Surg Clin. 2014 Feb;24(1):1-5. doi: 10.1016/j.thorsurg.2013.09.004. Epub 2013 Nov 9.
7
Building and maintaining the epithelium of the lung.构建和维持肺部的上皮组织。
J Clin Invest. 2012 Aug;122(8):2724-30. doi: 10.1172/JCI60519. Epub 2012 Aug 1.
8
Aerosol deposition in health and disease.气溶胶在健康和疾病中的沉积。
J Aerosol Med Pulm Drug Deliv. 2012 Jun;25(3):140-7. doi: 10.1089/jamp.2011.0916.
9
The impact of ageing on the barriers to drug delivery.衰老对药物传递障碍的影响。
J Control Release. 2012 Jul 20;161(2):389-98. doi: 10.1016/j.jconrel.2012.01.020. Epub 2012 Jan 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验